{"id":"https://genegraph.clinicalgenome.org/r/e7d8bfdb-c290-49da-b17f-d6978c5c7cbbv1.1","type":"EvidenceStrengthAssertion","dc:description":"CAPN5 was first reported in relation to autosomal dominant CAPN5-related vitreoretinopathy in 2012 in a patient described with described as neovascular inflammatory vitreoretinopathy, (Mahajan et al, PMID: 23055945). \nSix variants (all missense), reported in 10 probands in 6 publications (Mahajan et al, 2012, PMID: 23055945; Bassuk et al, 2015, PMID: 25856303; Randazzo et al, 2017, PMID: 29040051; Velez et al, 2018, PMID: 29472286; O’Keefe et al, 2019, PMID: 30986125; Tang et al, 2020, PMID: 32274441) are included in this curation, in addition to segregation data from analysis of a large family (Stone et al, 1992, PMID: 1284594) (Total Genetic Evidence: 7.8 points). \nThis gene-disease association is also supported by experimental evidence including expression data from RNA-Seq analysis (Schaefer et al, 2016, PMID: 27152965) and the phenotype observed in mouse models (Wert et al, 2014, PMID: 24381307; Wert et al, 2015, PMID: 25994508). In summary, CAPN5 is definitively associated with autosomal dominant CAPN5-related vitreoretinopathy. This classification was approved by the ClinGen Retina GCEP on August 5, 2021.\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/e7d8bfdb-c290-49da-b17f-d6978c5c7cbb","GCISnapshot":"https://genegraph.clinicalgenome.org/r/7d39e430-b1fc-43f1-957b-1c02eb66a69c","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/7d39e430-b1fc-43f1-957b-1c02eb66a69c_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10072","date":"2022-05-24T22:14:10.029Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/7d39e430-b1fc-43f1-957b-1c02eb66a69c_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10072","date":"2021-08-05T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7d39e430-b1fc-43f1-957b-1c02eb66a69c_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7d39e430-b1fc-43f1-957b-1c02eb66a69c_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/caaa19e0-3900-4e6f-ab30-778839e5eba5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8a81da57-26ae-48ca-a800-0b8e338c8f81","type":"Finding","dc:description":"Bulk RNA sequencing from human donor retina samples showed the transcript at a level of 4.63 fragments per kilobase of exon per million.  No significant splice variants were observed. Two antibodies against calpain-5 confirmed the expression in the photoreceptor cells of the donor human retinal tissue sections. No significant expression was observed in the nerve fiber layer, ganglion cell layer, inner nuclear layer, inner plexiform layer or RPE. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23055945","rdfs:label":"RNA Sequencing and Immunohistochemistry","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/fab08fdd-492f-4e13-a2c7-e37c68273109","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e33af25a-4923-428f-b528-244cbfeab7c6","type":"Finding","dc:description":"In this study multiple expression related experiments were performed including mRNA analysis in human and mouse retina and in retinoblastoma cells. Immunohistochemistry in mouse retina, and western blots on neuronal cancer cells and fractionated central nervous tissue extracts.\n\nIt was observed that CAPN5 is moderately expressed in retina but highly expressed in other tissues. It was also observed that CAPN5 is expressed at photoreceptor synapse and with mitochondria. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27152965","rdfs:label":"Multiple expression related experiments","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/7d39e430-b1fc-43f1-957b-1c02eb66a69c_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5125eac0-c553-460c-bd25-f1a480e9a493","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e810b0c-52ba-4d4e-94dd-c66634d8881d","type":"Finding","dc:description":"The mouse model expressing R243L allele in retina developed major features of ADNIV as observed in human subjects which shows that gain of function mutations in CAPN5 can cause ADNIV. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25994508","rdfs:label":"Mouse Model expressing R243L only in retina","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a155eddd-fb65-4cc7-966b-8d418faef4fd","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/33d8f62c-9623-4631-a518-d14edfc38ad9","type":"Finding","dc:description":"This study demonstrates that both human ADNIV patients and the hCAPN5-R243L lentiviral model show reduced visual response, photoreceptor degeneration within both the ONL and INL, and the presence of T cells and altered inflammatory gene expression, supporting that the R243L amino acid change found in human ADNIV patients is a disease-causing mutation. The hCAPN5-R243L disease allele is able to recapitulate aspects of the human ADNIV phenotype in wild-type mice. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24381307","rdfs:label":"Lentiviral transduction of exome variant into mouse retina","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5},{"id":"https://genegraph.clinicalgenome.org/r/7d39e430-b1fc-43f1-957b-1c02eb66a69c_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d08a6ab6-8ffe-4d17-8989-ef6d50ce7627","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d08a6ab6-8ffe-4d17-8989-ef6d50ce7627_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29472286","allele":{"id":"https://genegraph.clinicalgenome.org/r/8d703744-8e87-476a-beb1-ec87845c6e4c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004055.5(CAPN5):c.865C>T (p.Arg289Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10603137"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/d08a6ab6-8ffe-4d17-8989-ef6d50ce7627_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"CAPN5 mutants were expressed in cells to determine their activity. At normal intracellular calcium, both a catalytically inactive mutant (p.Cys81Ser) and the wild-type (WT) CAPN5 were inactive. The p.Arg243Leu mutant showed slight activation, whereas the p.Arg289Trp disease variant showed strong activation. Thus, CAPN5 p.Arg289Trp was hyperactive, autoproteolyzed even in the absence of calcium levels required to activate WT CAPN5, and displayed more proteolytic fragments than\np.Arg243Leu. \n\nIn another experiment, at elevated intracellular calcium, the WT CAPN5 became activated\nas expected, and the p.Arg289Trp maintained high hyperactivity (data not shown in manuscript). Introduction of the homologous mutation (p.Val301Trp) into purified CAPN1 catalytic core also led to increased enzymatic activity, further confirming that disruption of the Trp “wedge” by this mutation is a critical, conserved regulatory mechanism across calpains. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/b311e4f3-f387-4202-b412-b3e5febb0fb4","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b311e4f3-f387-4202-b412-b3e5febb0fb4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23055945","allele":{"id":"https://genegraph.clinicalgenome.org/r/0fa3c591-e736-478e-8625-6fc894db434b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004055.5(CAPN5):c.731T>C (p.Leu244Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130572"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/b311e4f3-f387-4202-b412-b3e5febb0fb4_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In current study, HEK293T cells were transfected with wildtype and p.Leu244Pro mutant constructs. Immunocytochemistry of HEK293T cells showed normal calpain-5 to be localized near the cell surface. Whereas p.Leu244Pro mutant was found largely within the cytoplasm. This suggests that the this variation may alter a membrane binding property of the protein. Furthermore, protein structure modeling showed that Leu244 is located in an alpha helical domain near the active site of the protein and the variant Leu244Pro is predicted to disrupt the helix which may interfere with the function of CAPN5 protein. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9cf69efa-24d3-4898-aa25-f5876e16fe83","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9cf69efa-24d3-4898-aa25-f5876e16fe83_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32274441","allele":{"id":"https://genegraph.clinicalgenome.org/r/54b2b174-e073-4731-9330-079c4c0cb773","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004055.5(CAPN5):c.728G>T (p.Arg243Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130571"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/9cf69efa-24d3-4898-aa25-f5876e16fe83_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional data was acquired from another study (PMID : 23055945) in which HEK293T cells were transfected with wildtype and p.Arg243Leu mutant constructs. Immunocytochemistry of HEK293T cells showed normal calpain-5 to be localized near the cell surface. Whereas p.Arg243Leu mutant was found largely within the cytoplasm. This suggests that the this variation may alter a membrane binding property of the protein. Furthermore, protein structure modeling showed that Arg243 is located near the active site of the protein and the charged Arginine residue is replaced by neutral Leucine which may interfere with the function of CAPN5 protein. In another study (PMID: 24381307), expression of the hCAPN5-R243L in a lentiviral vector under rhodopsin promoter with tandem green fluorescent protein (GFP) expression showed that disease allele elicits an ADNIV-like disease in mice.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9a19f5cd-4792-4b70-8906-1f3e0ab3c77b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9a19f5cd-4792-4b70-8906-1f3e0ab3c77b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23055945","allele":{"id":"https://genegraph.clinicalgenome.org/r/54b2b174-e073-4731-9330-079c4c0cb773"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/9a19f5cd-4792-4b70-8906-1f3e0ab3c77b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In current study, HEK293T cells were transfected with wildtype and p.Arg243Leu mutant constructs. Immunocytochemistry of HEK293T cells showed normal calpain-5 to be localized near the cell surface. Whereas p.Arg243Leu mutant was found largely within the cytoplasm. This suggests that the this variation may alter a membrane binding property of the protein. Furthermore, protein structure modeling showed that Arg243 is located near the active site of the protein and the charged Arginine residue is replaced by neutral Leucine which may interfere with the function of CAPN5 protein. In another study (PMID: 24381307), expression of the hCAPN5-R243L in a lentiviral vector under rhodopsin promoter with tandem green fluorescent protein (GFP) expression showed that disease allele elicits an ADNIV-like disease in mice.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4d78c696-6536-4b4c-8c30-71c37e8337f6","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4d78c696-6536-4b4c-8c30-71c37e8337f6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30986125","allele":{"id":"https://genegraph.clinicalgenome.org/r/8d703744-8e87-476a-beb1-ec87845c6e4c"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/4d78c696-6536-4b4c-8c30-71c37e8337f6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"This functional data comes from another study (PMID 29472286). CAPN5 mutants were expressed in cells to determine their activity. At normal intracellular calcium, both a catalytically inactive mutant (p.Cys81Ser) and the wild-type (WT) CAPN5 were inactive. The p.Arg243Leu mutant showed slight activation, whereas the p.Arg289Trp disease variant showed strong activation. Thus, CAPN5 p.Arg289Trp was hyperactive, autoproteolyzed even in the absence of calcium levels required to activate WT CAPN5, and displayed more proteolytic fragments than\np.Arg243Leu. \n\nIn another experiment, at elevated intracellular calcium, the WT CAPN5 became activated\nas expected, and the p.Arg289Trp maintained high hyperactivity (data not shown in manuscript). Introduction of the homologous mutation (p.Val301Trp) into purified CAPN1 catalytic core also led to increased enzymatic activity, further confirming that disruption of the Trp “wedge” by this mutation is a critical, conserved regulatory mechanism across calpains. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/9e5ac44e-0c01-4367-8038-bccda034485c","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e5ac44e-0c01-4367-8038-bccda034485c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29040051","allele":{"id":"https://genegraph.clinicalgenome.org/r/ce8daff7-0f31-4fdf-a0d5-ab93321fbe8e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004055.5(CAPN5):c.799G>A (p.Gly267Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/964215"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/92c4c2a6-caec-44b8-9761-d1e802e368e9","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/92c4c2a6-caec-44b8-9761-d1e802e368e9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25856303","allele":{"id":"https://genegraph.clinicalgenome.org/r/dd890514-962c-4604-8296-c84716b90074","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004055.5(CAPN5):c.750G>T (p.Lys250Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1052281"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/7d39e430-b1fc-43f1-957b-1c02eb66a69c_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11bc3d63-656c-4ed7-86a4-2359c165da8b_family_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1284594","rdfs:label":"ADNIV-1","family":{"id":"https://genegraph.clinicalgenome.org/r/11bc3d63-656c-4ed7-86a4-2359c165da8b","type":"Family","rdfs:label":"ADNIV-1","ethnicity":{"id":"cg:NotHispanicOrLatino"}},"phenotype":[{"id":"obo:HP_0025319"},{"id":"obo:HP_0030666"},{"id":"obo:HP_0000518"},{"id":"obo:HP_0007984"},{"id":"obo:HP_0100014"},{"id":"obo:HP_0007703"},{"id":"obo:HP_0011505"},{"id":"obo:HP_0000618"},{"id":"obo:HP_0000541"},{"id":"obo:HP_0007902"},{"id":"obo:HP_0030662"}],"phenotypeFreeText":"Neovascular glaucoma","phenotypePositiveAllelePositive":34,"publishedLodScore":11.9},{"id":"https://genegraph.clinicalgenome.org/r/99d82888-b5d9-4c7e-99dd-23937057e47d_proband_segregation","type":"FamilyCosegregation","dc:description":"Not clear which family members were genotyped. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23055945","rdfs:label":"ADNIV-3","estimatedLodScore":3.01,"family":{"id":"https://genegraph.clinicalgenome.org/r/99d82888-b5d9-4c7e-99dd-23937057e47d","type":"Family","rdfs:label":"ADNIV-3","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/85342e5d-54cd-4de1-9cad-1094c3295853","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23055945","rdfs:label":"Unknown-3","allele":{"id":"https://genegraph.clinicalgenome.org/r/0fa3c591-e736-478e-8625-6fc894db434b"},"detectionMethod":"STR based genotyping was performed on all family members. It is unclear how many affected and unaffected members of this family were subjected to STR-based genotyping and there is no published LOD score. It also unknown if presence or absence of CNVs/SVs was evaluated in the 86 genes present in the 6 Mb ADNIV interval. It is also unclear how many affected and unaffected members were subjected to sanger and or SSCP to confirm segregation of the variant.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Linkage analysis","phenotypes":["obo:HP_0011505","obo:HP_0100014","obo:HP_0000580","obo:HP_0007773","obo:HP_0000518","obo:HP_0000541","obo:HP_0011497","obo:HP_0007902","obo:HP_0000667","obo:HP_0000501","obo:HP_0000554","obo:HP_0002960","obo:HP_0000618","obo:HP_0030666","obo:HP_0007984"],"secondTestingMethod":"Exome sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/b311e4f3-f387-4202-b412-b3e5febb0fb4_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":15,"phenotypes":["obo:HP_0000667","obo:HP_0011497","obo:HP_0002960","obo:HP_0000541","obo:HP_0000618","obo:HP_0007984","obo:HP_0000501","obo:HP_0007902","obo:HP_0000554","obo:HP_0030666","obo:HP_0000518","obo:HP_0011505","obo:HP_0100014","obo:HP_0007773","obo:HP_0000580"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/85342e5d-54cd-4de1-9cad-1094c3295853"}},{"id":"https://genegraph.clinicalgenome.org/r/82106929-5c97-4789-a5c2-9b4174098572_proband_segregation","type":"FamilyCosegregation","dc:description":"Authors mentioned that the variant segregated in all affected members of the family (number unknown) and was absent from all unaffected family members. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23055945","rdfs:label":"ADNIV-1","estimatedLodScore":9.63,"family":{"id":"https://genegraph.clinicalgenome.org/r/82106929-5c97-4789-a5c2-9b4174098572","type":"Family","rdfs:label":"ADNIV-1","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/d0b905d0-4291-441d-864a-5b49dd3e008c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23055945","rdfs:label":"Unknown-1","allele":{"id":"https://genegraph.clinicalgenome.org/r/54b2b174-e073-4731-9330-079c4c0cb773"},"detectionMethod":"STR based genotyping was performed on all family members. 3 members were also subjected to  Affymetrix GeneChip Human Mapping 50K Array. \nIt is unclear how many affected and unaffected members of this family were subjected to STR-based genotyping. It also unknown if presence or absence of CNVs/SVs was evaluated in the 86 genes present in the 6 Mb ADNIV interval.  \n\nIt is also unclear how many affected and unaffected members were subjected to sanger and or SSCP to confirm segregation of the variant.  ","firstTestingMethod":"Linkage analysis","secondTestingMethod":"Exome sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/5d30af9e-97aa-430d-a012-10d6544d5099_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23055945","allele":{"id":"https://genegraph.clinicalgenome.org/r/54b2b174-e073-4731-9330-079c4c0cb773"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Psoriasis in one individual. ","phenotypePositiveAllelePositive":33,"phenotypes":["obo:HP_0000618","obo:HP_0000580","obo:HP_0007984","obo:HP_0007902","obo:HP_0000667","obo:HP_0000501","obo:HP_0011497","obo:HP_0100014","obo:HP_0000554","obo:HP_0007773","obo:HP_0030666","obo:HP_0011505","obo:HP_0000541","obo:HP_0000518"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/d0b905d0-4291-441d-864a-5b49dd3e008c"},"publishedLodScore":11.9,"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/0267c5b3-58e3-4a4d-864d-9709e39122d5_proband_segregation","type":"FamilyCosegregation","dc:description":"Not clear which family members were genotyped. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23055945","rdfs:label":"ADNIV-2","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/0267c5b3-58e3-4a4d-864d-9709e39122d5","type":"Family","rdfs:label":"ADNIV-2","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/765cd1ed-eaad-4f78-b1d7-6a9ce2dbc5ad","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23055945","rdfs:label":"Unknown-2","allele":{"id":"https://genegraph.clinicalgenome.org/r/54b2b174-e073-4731-9330-079c4c0cb773"},"detectionMethod":"STR based genotyping was performed on all family members. It is unclear how many affected and unaffected members of this family were subjected to STR-based genotyping. It also unknown if presence or absence of CNVs/SVs was evaluated in the 86 genes present in the 6 Mb ADNIV interval. It is also unclear how many affected and unaffected members were subjected to sanger and or SSCP to confirm segregation of the variant.\n","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Linkage analysis","secondTestingMethod":"Exome sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/9a19f5cd-4792-4b70-8906-1f3e0ab3c77b_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":5,"phenotypes":["obo:HP_0100014","obo:HP_0000541","obo:HP_0000518","obo:HP_0011497","obo:HP_0000580","obo:HP_0000667","obo:HP_0000554","obo:HP_0000501","obo:HP_0002960","obo:HP_0007984","obo:HP_0007902","obo:HP_0011505","obo:HP_0000618","obo:HP_0007773","obo:HP_0030666"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/765cd1ed-eaad-4f78-b1d7-6a9ce2dbc5ad"}},{"id":"https://genegraph.clinicalgenome.org/r/d5d5f51d-f28a-45ac-85cb-04792c3e6334_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25856303","rdfs:label":"ADNIV","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/d5d5f51d-f28a-45ac-85cb-04792c3e6334","type":"Family","rdfs:label":"ADNIV","member":{"id":"https://genegraph.clinicalgenome.org/r/9886a41e-583a-47df-a532-ab8a474ff8fe","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25856303","rdfs:label":"II:1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":23,"allele":{"id":"https://genegraph.clinicalgenome.org/r/dd890514-962c-4604-8296-c84716b90074"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Intraocular fibrosis","phenotypes":["obo:HP_0000518","obo:HP_0000554","obo:HP_0011505","obo:HP_0030666","obo:HP_0000546","obo:HP_0000541"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/92c4c2a6-caec-44b8-9761-d1e802e368e9_variant_evidence_item"}}},"phenotypeFreeText":"Intraocular fibrosis","phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0011505","obo:HP_0000541","obo:HP_0030666","obo:HP_0000518","obo:HP_0000546","obo:HP_0000554"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/9886a41e-583a-47df-a532-ab8a474ff8fe"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/98e6fdb8-f86d-4db6-8559-c2becaf0ddb1","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/98e6fdb8-f86d-4db6-8559-c2becaf0ddb1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32274441","allele":{"id":"https://genegraph.clinicalgenome.org/r/54b2b174-e073-4731-9330-079c4c0cb773"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/98e6fdb8-f86d-4db6-8559-c2becaf0ddb1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional data was acquired from another study (PMID : 23055945) in which HEK293T cells were transfected with wildtype and p.Arg243Leu mutant constructs. Immunocytochemistry of HEK293T cells showed normal calpain-5 to be localized near the cell surface. Whereas p.Arg243Leu mutant was found largely within the cytoplasm. This suggests that the this variation may alter a membrane binding property of the protein. Furthermore, protein structure modeling showed that Arg243 is located near the active site of the protein and the charged Arginine residue is replaced by neutral Leucine which may interfere with the function of CAPN5 protein. In another study (PMID: 24381307), expression of the hCAPN5-R243L in a lentiviral vector under rhodopsin promoter with tandem green fluorescent protein (GFP) expression showed that disease allele elicits an ADNIV-like disease in mice. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6436d5d4-1e33-451a-b882-d9cae06eac51","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6436d5d4-1e33-451a-b882-d9cae06eac51_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29040051","allele":{"id":"https://genegraph.clinicalgenome.org/r/8cc6552a-8426-496e-9ccb-e985a752085c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004055.5(CAPN5):c.1126G>A (p.Gly376Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6196694"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/5d30af9e-97aa-430d-a012-10d6544d5099","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5d30af9e-97aa-430d-a012-10d6544d5099_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/5d30af9e-97aa-430d-a012-10d6544d5099_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In current study, HEK293T cells were transfected with wildtype and p.Arg243Leu mutant constructs. Immunocytochemistry of HEK293T cells showed normal calpain-5 to be localized near the cell surface. Whereas p.Arg243Leu mutant was found largely within the cytoplasm. This\nsuggests that the this variation may alter a membrane binding property of the protein.\n\nFurthermore, protein structure modeling showed that Arg243 is located near the active site of the protein and the charged Arginine residue is replaced by neutral Leucine which may interfere with the function of CAPN5 protein. \n\nIn another study (PMID: 24381307), expression of the hCAPN5-R243L in a lentiviral vector under rhodopsin promoter with tandem green fluorescent protein (GFP) expression showed that disease allele elicits an ADNIV-like disease in mice. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":7.8}],"evidenceStrength":"Definitive","sequence":4483,"specifiedBy":"GeneValidityCriteria8","strengthScore":12.8,"subject":{"id":"https://genegraph.clinicalgenome.org/r/wsVsyDUvHWU","type":"GeneValidityProposition","disease":"obo:MONDO_0100450","gene":"hgnc:1482","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_7d39e430-b1fc-43f1-957b-1c02eb66a69c-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}